Xichen Lin - 03 Jun 2024 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Jun Yoon, Attorney-in-Fact
Issuer symbol
GPCR
Transactions as of
03 Jun 2024
Net transactions value
-$1,645,463
Form type
4
Filing time
05 Jun 2024, 19:38:50 UTC
Previous filing
20 Mar 2024
Next filing
03 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GPCR Ordinary Shares Options Exercise $36,108 +106,200 +124% $0.3400* 191,907 03 Jun 2024 Direct
transaction GPCR Ordinary Shares Conversion of derivative security $0 -106,200 -55% $0.000000 85,707 03 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GPCR Share Option (right to buy) Options Exercise $0 -106,200 -33% $0.000000 213,800 03 Jun 2024 Ordinary Shares 106,200 $0.3400 Direct F2, F3
transaction GPCR American Depositary Shares Conversion of derivative security $0 +35,400 $0.000000 35,400 03 Jun 2024 Ordinary Shares 106,200 Direct F4, F5
transaction GPCR American Depositary Shares Sale $796,500 -17,700 -50% $45.00 17,700 03 Jun 2024 Ordinary Shares 53,100 Direct F4, F6
transaction GPCR American Depositary Shares Sale $885,071 -17,700 -100% $50.00 0 03 Jun 2024 Ordinary Shares 53,100 Direct F4, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares were converted into American Depositary Shares as reported in Table II above.
F2 1/4 of the shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
F3 This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 106,200 Ordinary Shares.
F4 Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
F5 106,200 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 35,400 American Depositary Shares.
F6 The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on December 28, 2023.
F7 The weighted average sale price for the transaction reported was $50.004, and the range of prices were between $50.00 and $50.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.